Antiangiogenesis therapies  
 
The goal is to target the blood supply that feeds tumors.
 

Antibodies (monoclonal) with or without chemotherapy

Targets a specific receptor type on the surface of malignant cells 

Bispecific antibodies

Targets two receptor types on the malignant cells with one antibody

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Antibodies (monoclonal) 

"Antibodies

Biologics - Cytokines | Biological response modifiers

BL22 

BL22 immunotoxin can find tumor cells that express cd22 and kill them without harming normal cells.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
   

Antigen-specific antibodies:

Antisense (anti-bcl-2)  (Oblimersen sodium, Genasense)
 
Antisense therapy inhibits cell production of bcl-2, a protein that is thought to inhibit cell death and increase resistance to cancer therapies.  Thus, the goal of antisense therapy is to sensitize cancer cells to cancer treatments. It may also have activity as a single agent.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Arsenic trioxide
 
Arsenic trioxide may induce cell death (apoptosis) and normalization (differentiation) thru novel pathway(s). Approved for leukemia.

Bendamustine 
 
Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazol group.  It has shown activity against refractory lymphomas - lymphomas resistant to treatment.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
 

Bexxar (Tositumomab, Iodine I 131)
 
Radioimmunotherapy for CD20 positive lymphomas.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 

BMS-247550 
 
Epothilone B-Analog. Primarily for relapsed aggressive lymphomas.

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Bryostatin 
 
Possible mechanism of action: "Bryostatin-1 is believed to bind to the regulatory domain of the PKC enzyme suggesting a mechanism of action distinct from other kinase modulators in development." - gpc-ag.com

TOPIC SEARCH: Mechanisms PubMed 
Outcome ASCO | Medscape | PubMed
Safety ASCO | PubMed 
  

Chemotherapy-based treatment: All phases | Phase I | Phase II | Phase III  

Chemotherapy is a general term for a systemic therapy. 

Click here for details on meaning of Phase I, II, III studies.

Chemotherapy with biologics 

High Dose Cytoxan and biologics (by request) 

Enzyme Inhibiting Therapies

Enzastaurin

Enzastaurin (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cbeta isozyme.

Graft versus Host disease 

acute GvHD  | chronic GvHD  
 
Graft vs. Host Disease (GvHD) -  a frequent complication of allogeneic bone marrow transplant in which the donor's bone marrow cells attacks the patient's organs and tissue. GvHD tends to be more severe in patients receiving mismatched transplants from family member and in patients receiving unrelated donor transplants.  See GvHD for more detail.

Immunotherapy without chemo or radiotherapy | phase I for this type

CTLA4 

EBV-specific lymphocyte therapy

Peripheral blood lymphocyte therapy 

Immune-modulator therapy without chemotherapy
 
The goal of this investigative treatment type is to modify the immune system in order to fight lymphoma or enhance other treatments.

Also see Vaccine below

Gallium Nitrate
 
The goal is induce lymphoma cell death, selectively.  Trials appear to be closed as of 11/2005.  Outcome data has not been presented yet.

HDAC inhibitors
 
"HDAC inhibitor MS-275, a benzamide derivative, has demonstrated potent and unique cytotoxicity and anticancer activity in vitro (test tube) in human tumor cell lines and, more importantly, in vivo in human tumor xenografts." 

All studies for

tyrosine kinase inhibitors

All studies for 

"Lenalidomide...  may decrease the production of cytokine and growth factors decreasing the growth of the cells or new blood vessels for the cells. ...  it could also improve the function of natural killer T cells, and enhance immunity.

Lenalidomide is currently approved by the FDA for the treatment of multiple myeloma, another type of cancer that affects circulating plasma cells, which produce antibodies. Lenalidomide is currently awaiting FDA approval for CLL and NHL."

Liposomal versions of biologics and chemotherapy
 
Liposomal delivery of treatments may reduce side effects and/or improve efficacy.

Motexafin Gadolinium 
 
A radio-sensitizing agent that combines preferential tumor uptake with detection of drug localization by magnetic resonance imaging.

All for lymphomas

ONTAK
  
Ontak is a fusion protein which adheres to the interleukin-2 receptor on the malignant cell which may cause cell death.

Pixantrone 
 
Might have similar activity against aggressive lymphomas as doxorubicin, with less cardio toxicity. -  prnews 

Radiotherapy all stages - Stage I | Stage II | Stage III | Stage IV